Why Is SYRE Stock Dropping Today? Spyre Therapeutics Falls After SKYWAY RA Trial Data

Spyre Therapeutics (SYRE) shares fell 14.31% in post-market trading Tuesday after the company reported topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial for SPY072. While the drug showed statistical significance versus placebo, the magnitude of effect fell short of the company's internal threshold to prioritize monotherapy development in RA.

What Did Spyre Announce?

On August 25, the Waltham-based biotech released data from the RA arm of its Phase 2 SKYWAY basket trial. Both tested doses of SPY002 — an extended half-life antibody targeting the TL1A cytokine — demonstrated statistically significant benefits over placebo on at least one primary, key secondary, or exploratory endpoint.

The low dose met the primary endpoint, producing a -1.9 change from baseline in DAS28-CRP compared to -1.3 for placebo at Week 12, with a p-value of less than 0.05. It also delivered a nominal ACR50 response rate of 38% versus 19% for placebo. The high dose achieved a 63% ACR20 response rate versus 43% for placebo, with broadly similar results across advanced-therapy-naive and experienced patient subgroups.

Safety was consistent with the TL1A inhibitor class. Adverse event rates were 27% for active treatment versus 36% for placebo, with one serious treatment-emergent adverse event per arm.

Despite the positive signals, the company said the magnitude of effect did not meet its target to prioritize SPY072 as a standalone RA therapy. The data provide proof-of-mechanism for TL1A inhibition in rheumatoid arthritis, and Spyre is shifting its emphasis toward combination strategies and broader TL1A applications across other autoimmune indications.

Why Does The Pivot Matter?

For a clinical-stage company with no product revenue, every development decision shapes the near-term optionality in the pipeline. Deprioritizing RA monotherapy means the path to commercialization through that specific indication has become less direct — even though the drug showed promise.

The data do reinforce the broader thesis behind Spyre's TL1A platform. SPY072's extended half-life of approximately 75 days — more than three times that of first-generation anti-TL1A antibodies — positions it for potentially less frequent dosing in combination regimens. That differentiation could matter across the company's expanding rheumatology and immunology programs.

The company also has a combination program, SPY772, evaluating SPY072 plus an anti-IL-17A/F antibody in hidradenitis suppurativa, with Phase 2 SKYLIGHT results expected in late 2027 or early 2028. In inflammatory bowel disease, Spyre's pipeline includes pairwise combinations targeting alpha-4-beta-7, TL1A, and IL-23, which represent the company's core focus.

Still, the decision signals that the RA monotherapy path — one of the largest autoimmune markets — will not be a near-term value driver for SYRE investors.

What Should Investors Watch Next?

The immediate question is whether the regular trading session confirms the post-market selloff. Post-market liquidity is thinner, and volume during the extended session was well below the 20-day average, meaning the full market hasn't had a chance to price in the data.

Looking forward, Spyre has several catalysts on deck. Phase 2 readouts for SPY072 in psoriatic arthritis and axial spondyloarthritis are on track for the fourth quarter of 2026. The company also expects SPY003 Part A data from the SKYLINE trial in September, plus additional IBD combination readouts through 2027.

With SYRE shares up roughly 45% over the past three months, the post-market decline partially offsets that run. Whether the market ultimately views the RA results as a manageable setback — proof-of-mechanism confirmed, other indications intact — or a signal that TL1A monotherapy carries more risk than hoped will depend on how the stock trades once regular-session participants return.